BiondVax Pharmaceuticals (BVXV) Getting Favorable Press Coverage, Study Shows
News stories about BiondVax Pharmaceuticals (NASDAQ:BVXV) have trended positive on Sunday, according to Accern. The research group identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BiondVax Pharmaceuticals earned a media sentiment score of 0.27 on Accern’s scale. Accern also assigned news articles about the company an impact score of 50.1141308246618 out of 100, meaning that recent news coverage is somewhat likely to have an effect on the company’s share price in the immediate future.
Shares of BiondVax Pharmaceuticals (BVXV) opened at 7.1374 on Friday. BiondVax Pharmaceuticals has a 12-month low of $3.04 and a 12-month high of $8.50. The stock’s market capitalization is $32.04 million. The company has a 50-day moving average of $7.16 and a 200-day moving average of $7.16.
Separately, ValuEngine downgraded shares of BiondVax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd.
BiondVax Pharmaceuticals Company Profile
BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company. The Company holds a worldwide exclusive license granted by Yeda Research and Development Ltd., the commercial arm of the Weizmann Institute, Israel, for developing, manufacturing and commercializing the flu vaccine. BiondVax Pharmaceuticals Ltd develops a biopharmaceutical universal flu vaccine, designed to provide multi-season and multi-strain protection against some human influenza virus strains, including both seasonal and pandemic flu strains.
Receive News & Ratings for BiondVax Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BiondVax Pharmaceuticals Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.